share_log

6-K: Report of foreign private issuer (related to financial reporting)

6-K: Report of foreign private issuer (related to financial reporting)

6-K：外国发行人报告（业绩相关）
美股SEC公告 ·  09/26 16:33

Moomoo AI 已提取核心信息

Alterity Therapeutics Limited, a development stage biotechnology company, reported a net loss of A$19,123,464 and a net operating cash outflow of A$12,605,824 for the fiscal year ended June 30, 2024. The company, which focuses on developing therapeutic drugs for neurodegenerative diseases, acknowledged the need for additional capital to continue its research and development programs. Despite the losses, Alterity has a tax incentive receivable of A$4,019,285 and remains optimistic about its ability to raise necessary funds. The company's financial statements were prepared under the assumption that it will continue as a going concern, with the acknowledgment of material uncertainties that may cast significant doubt on this assumption. Alterity's financial activities are subject to risks including market risk, credit risk, and liquidity risk, with management actively monitoring cash flow forecasts. The company's shares are listed on the ASX under the symbol 'ATH' and on the NASDAQ Capital Market under 'ATHE'.
Alterity Therapeutics Limited, a development stage biotechnology company, reported a net loss of A$19,123,464 and a net operating cash outflow of A$12,605,824 for the fiscal year ended June 30, 2024. The company, which focuses on developing therapeutic drugs for neurodegenerative diseases, acknowledged the need for additional capital to continue its research and development programs. Despite the losses, Alterity has a tax incentive receivable of A$4,019,285 and remains optimistic about its ability to raise necessary funds. The company's financial statements were prepared under the assumption that it will continue as a going concern, with the acknowledgment of material uncertainties that may cast significant doubt on this assumption. Alterity's financial activities are subject to risks including market risk, credit risk, and liquidity risk, with management actively monitoring cash flow forecasts. The company's shares are listed on the ASX under the symbol 'ATH' and on the NASDAQ Capital Market under 'ATHE'.
alterity therapeutics有限公司是一家处于发展阶段的生物技术公司，截至2024年6月30日止的财政年度报告净亏损为19,123,464澳元，净经营现金流出为12,605,824澳元。该公司致力于开发治疗神经退行性疾病的药物，承认需要额外资本继续其研发项目。尽管亏损，alterity具有4,019,285澳元的税收激励应收款，并对筹集必要资金的能力持乐观态度。公司的财务报表假设其将继续作为持续经营实体，并承认可能对该假设产生重大疑虑的重大不确定性。alterity的财务活动面临市场风险、信用风险和流动性风险，管理团队积极监控现金流预测。该公司的股票在澳大利亚证券交易所上市，交易代码为'ATH'，并在纳斯达克资本市场上市，交易代码为'ATHE'。
alterity therapeutics有限公司是一家处于发展阶段的生物技术公司，截至2024年6月30日止的财政年度报告净亏损为19,123,464澳元，净经营现金流出为12,605,824澳元。该公司致力于开发治疗神经退行性疾病的药物，承认需要额外资本继续其研发项目。尽管亏损，alterity具有4,019,285澳元的税收激励应收款，并对筹集必要资金的能力持乐观态度。公司的财务报表假设其将继续作为持续经营实体，并承认可能对该假设产生重大疑虑的重大不确定性。alterity的财务活动面临市场风险、信用风险和流动性风险，管理团队积极监控现金流预测。该公司的股票在澳大利亚证券交易所上市，交易代码为'ATH'，并在纳斯达克资本市场上市，交易代码为'ATHE'。
有用
没用

该公告为独立文件：

独立文件1

独立文件2

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间